| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 690 @ USD 57.71 | USD 39,820 | The ETF bought 690 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 57.71 compared to the previous average buy price of 22.7392. This is 153.8% higher than average price of previous purchases of ARWR. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 780 @ USD 3.86 | USD 3,011 | The ETF bought 780 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 3.86 compared to the previous average buy price of 1.37291. This is 181.2% higher than average price of previous purchases of IRWD. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.64 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.64. The average price that ABCL shares were previous bought at was USD 3.89641. The current market price is -6.6% lower than average price they were purchased at. USD 0 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ABUS - Arbutus Biopharma Corp | HOLD | 0 @ USD 4.41 | USD 0 | The current share valuation price of ABUS based on adjusted close was USD 4.41. The average price that ABUS shares were previous bought at was USD 3.7136. The current market price is 18.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Arbutus Biopharma Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 24.81 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 24.81. The average price that ACAD shares were previous bought at was USD 21.18. The current market price is 17.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 2.93 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 2.93. The average price that ACIU shares were previous bought at was USD 2.47625. The current market price is 18.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of AC Immune Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 73.25 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 73.25. The average price that ACLX shares were previous bought at was USD 72.9036. The current market price is 0.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ADMA - ADMA Biologics Inc | HOLD | 0 @ USD 19.14 | USD 0 | The current share valuation price of ADMA based on adjusted close was USD 19.14. The average price that ADMA shares were previous bought at was USD 17.3947. The current market price is 10.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of ADMA Biologics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 19.72 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 19.72. The average price that ADPT shares were previous bought at was USD 12.3604. The current market price is 59.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AGIO - Agios Pharm | HOLD | 0 @ USD 29.04 | USD 0 | The current share valuation price of AGIO based on adjusted close was USD 29.04. The average price that AGIO shares were previous bought at was USD 35.9917. The current market price is -19.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Agios Pharm however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AKRO - Akero Therapeutics Inc | HOLD | 0 @ USD 54.35 | USD 0 | The current share valuation price of AKRO based on adjusted close was USD 54.35. The average price that AKRO shares were previous bought at was USD 49.6794. The current market price is 9.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Akero Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ALEC - Alector Inc | HOLD | 0 @ USD 1.35 | USD 0 | The current share valuation price of ALEC based on adjusted close was USD 1.35. The average price that ALEC shares were previous bought at was USD 1.84476. The current market price is -26.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Alector Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 29.72 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 29.72. The average price that ALKS shares were previous bought at was USD 30.286. The current market price is -1.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.42 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.42. The average price that ALLO shares were previous bought at was USD 1.33247. The current market price is 6.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 445.12 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 445.12. The average price that ALNY shares were previous bought at was USD 381.556. The current market price is 16.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ALT - Altitude Group Plc | HOLD | 0 @ USD 5.17001 | USD 0 | The current share valuation price of ALT based on adjusted close was USD 5.17001. The average price that ALT shares were previous bought at was USD 5.15267. The current market price is 0.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Altitude Group Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 344.57 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 344.57. The average price that AMGN shares were previous bought at was USD 291.965. The current market price is 18.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 15 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 15. The average price that AMLX shares were previous bought at was USD 7.47651. The current market price is 100.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AMPH - Amphastar P | HOLD | 0 @ USD 27.36 | USD 0 | The current share valuation price of AMPH based on adjusted close was USD 27.36. The average price that AMPH shares were previous bought at was USD 25.5854. The current market price is 6.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Amphastar P however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | HOLD | 0 @ USD 12.52 | USD 0 | The current share valuation price of AMRX based on adjusted close was USD 12.52. The average price that AMRX shares were previous bought at was USD 9.11659. The current market price is 37.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Amneal Pharmaceuticals, Inc. Class A Common Stock however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 42.16 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 42.16. The average price that ANAB shares were previous bought at was USD 25.5262. The current market price is 65.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ANIP - ANI Pharmaceuticals Inc | HOLD | 0 @ USD 84.36 | USD 0 | The current share valuation price of ANIP based on adjusted close was USD 84.36. The average price that ANIP shares were previous bought at was USD 72.7138. The current market price is 16.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of ANI Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| APGE - Apogee Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 70.39 | USD 0 | The current share valuation price of APGE based on adjusted close was USD 70.39. The average price that APGE shares were previous bought at was USD 46.0092. The current market price is 53.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Apogee Therapeutics, Inc. Common Stock however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| APLS - Apellis Pharmaceuticals Inc | HOLD | 0 @ USD 21.59 | USD 0 | The current share valuation price of APLS based on adjusted close was USD 21.59. The average price that APLS shares were previous bought at was USD 20.9406. The current market price is 3.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Apellis Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.80001 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.80001. The average price that ARCT shares were previous bought at was USD 13.7777. The current market price is -50.6% lower than average price they were purchased at. USD 0 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ARDX - Ardelyx Inc | HOLD | 0 @ USD 5.93 | USD 0 | The current share valuation price of ARDX based on adjusted close was USD 5.93. The average price that ARDX shares were previous bought at was USD 4.73646. The current market price is 25.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Ardelyx Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ARGX - argenx NV ADR | HOLD | 0 @ USD 917.63 | USD 0 | The current share valuation price of ARGX based on adjusted close was USD 917.63. The average price that ARGX shares were previous bought at was USD 666.48. The current market price is 37.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of argenx NV ADR however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ARQT - Arcutis Biotherapeutics Inc | HOLD | 0 @ USD 30.96 | USD 0 | The current share valuation price of ARQT based on adjusted close was USD 30.96. The average price that ARQT shares were previous bought at was USD 17.4254. The current market price is 77.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Arcutis Biotherapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 12.42 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 12.42. The average price that ARVN shares were previous bought at was USD 9.05145. The current market price is 37.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ASND - Ascendis Pharma AS | HOLD | 0 @ USD 210.01 | USD 0 | The current share valuation price of ASND based on adjusted close was USD 210.01. The average price that ASND shares were previous bought at was USD 181.107. The current market price is 16.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Ascendis Pharma AS however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 16.37 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 16.37. The average price that AUPH shares were previous bought at was USD 9.84525. The current market price is 66.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AUTL - Autolus Therapeutics Ltd | HOLD | 0 @ USD 1.37 | USD 0 | The current share valuation price of AUTL based on adjusted close was USD 1.37. The average price that AUTL shares were previous bought at was USD 1.7999. The current market price is -23.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Autolus Therapeutics Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AVDL - Avadel Pharmaceuticals PLC | HOLD | 0 @ USD 21.4 | USD 0 | The current share valuation price of AVDL based on adjusted close was USD 21.4. The average price that AVDL shares were previous bought at was USD 12.0642. The current market price is 77.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Avadel Pharmaceuticals PLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 3.05 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 3.05. The average price that AVIR shares were previous bought at was USD 3.30422. The current market price is -7.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of Atea Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 3.86001 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 3.86001. The average price that AVXL shares were previous bought at was USD 8.94425. The current market price is -56.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Anavex Life Sciences Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 150.98 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 150.98. The average price that AXSM shares were previous bought at was USD 117.902. The current market price is 28.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| AZN - AstraZeneca PLC | HOLD | 0 @ USD 93.32 | USD 0 | The current share valuation price of AZN based on adjusted close was USD 93.32. The average price that AZN shares were previous bought at was USD 76.185. The current market price is 22.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 71.72 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 71.72. The average price that BBIO shares were previous bought at was USD 46.9521. The current market price is 52.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of BridgeBio Pharma Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.1 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.1. The average price that BCRX shares were previous bought at was USD 8.17782. The current market price is -13.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 7.31 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 7.31. The average price that BCYC shares were previous bought at was USD 8.384. The current market price is -12.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Bicycle Therapeutics Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 25.03 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 25.03. The average price that BEAM shares were previous bought at was USD 20.8125. The current market price is 20.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 181.94 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 181.94. The average price that BIIB shares were previous bought at was USD 141.545. The current market price is 28.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BMEA - Biomea Fusion Inc | HOLD | 0 @ USD 1.07 | USD 0 | The current share valuation price of BMEA based on adjusted close was USD 1.07. The average price that BMEA shares were previous bought at was USD 1.67254. The current market price is -36.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Biomea Fusion Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 55.52 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 55.52. The average price that BMRN shares were previous bought at was USD 57.9403. The current market price is -4.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Biomarin Pharmaceutical Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| BNTX - BioNTech SE | HOLD | 0 @ USD 102.7 | USD 0 | The current share valuation price of BNTX based on adjusted close was USD 102.7. The average price that BNTX shares were previous bought at was USD 104.923. The current market price is -2.1% lower than average price they were purchased at. USD 0 compared to the previous valuation of BioNTech SE however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 11.74 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 11.74. The average price that CGEM shares were previous bought at was USD 8.11046. The current market price is 44.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Cullinan Oncology LLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 44.84 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 44.84. The average price that CGON shares were previous bought at was USD 31.0802. The current market price is 44.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CNTA - Centessa Pharmaceuticals PLC ADR | HOLD | 0 @ USD 28.98 | USD 0 | The current share valuation price of CNTA based on adjusted close was USD 28.98. The average price that CNTA shares were previous bought at was USD 17.4527. The current market price is 66.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Centessa Pharmaceuticals PLC ADR however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| COGT - Cogent Biosciences Inc | HOLD | 0 @ USD 40.39 | USD 0 | The current share valuation price of COGT based on adjusted close was USD 40.39. The average price that COGT shares were previous bought at was USD 13.2009. The current market price is 206.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Cogent Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| COLL - Collegium Pharmaceutical Inc | HOLD | 0 @ USD 46.23 | USD 0 | The current share valuation price of COLL based on adjusted close was USD 46.23. The average price that COLL shares were previous bought at was USD 33.0234. The current market price is 40.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Collegium Pharmaceutical Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CRNX - Crinetics Pharmaceuticals Inc | HOLD | 0 @ USD 46.03 | USD 0 | The current share valuation price of CRNX based on adjusted close was USD 46.03. The average price that CRNX shares were previous bought at was USD 35.7325. The current market price is 28.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Crinetics Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CRSP - Crispr Therapeutics AG | HOLD | 0 @ USD 53.3 | USD 0 | The current share valuation price of CRSP based on adjusted close was USD 53.3. The average price that CRSP shares were previous bought at was USD 52.622. The current market price is 1.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Crispr Therapeutics AG however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 39.94 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 39.94. The average price that CSTL shares were previous bought at was USD 23.1925. The current market price is 72.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CVAC - CureVac NV | HOLD | 0 @ USD 5.48 | USD 0 | The current share valuation price of CVAC based on adjusted close was USD 5.48. The average price that CVAC shares were previous bought at was USD 4.88628. The current market price is 12.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of CureVac NV however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| CYTK - Cytokinetics Inc | HOLD | 0 @ USD 68.15 | USD 0 | The current share valuation price of CYTK based on adjusted close was USD 68.15. The average price that CYTK shares were previous bought at was USD 45.0807. The current market price is 51.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Cytokinetics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.41 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.41. The average price that DAWN shares were previous bought at was USD 7.57523. The current market price is 24.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 19.4 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 19.4. The average price that DNLI shares were previous bought at was USD 15.4394. The current market price is 25.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Denali Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 11.43 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 11.43. The average price that DVAX shares were previous bought at was USD 10.5808. The current market price is 8.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DYN - Dyne Therapeutics Inc | HOLD | 0 @ USD 21.17 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 21.17. The average price that DYN shares were previous bought at was USD 13.4448. The current market price is 57.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Dyne Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | HOLD | 0 @ USD 21.17 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 21.17. The average price that DYN shares were previous bought at was USD 13.4448. The current market price is 57.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of DYNAGREEN EN.PR.GR.H YC 1 however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 2.4 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 2.4. The average price that EDIT shares were previous bought at was USD 2.70875. The current market price is -11.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Editas Medicine Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ELVN - Enliven Therapeutics Inc. | HOLD | 0 @ USD 21.71 | USD 0 | The current share valuation price of ELVN based on adjusted close was USD 21.71. The average price that ELVN shares were previous bought at was USD 20.5187. The current market price is 5.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Enliven Therapeutics Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EOLS - Evolus Inc | HOLD | 0 @ USD 7.03999 | USD 0 | The current share valuation price of EOLS based on adjusted close was USD 7.03999. The average price that EOLS shares were previous bought at was USD 8.97813. The current market price is -21.6% lower than average price they were purchased at. USD 0 compared to the previous valuation of Evolus Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ERAS - Erasca Inc | HOLD | 0 @ USD 3.13 | USD 0 | The current share valuation price of ERAS based on adjusted close was USD 3.13. The average price that ERAS shares were previous bought at was USD 1.78343. The current market price is 75.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Erasca Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EWTX - Edgewise Therapeutics Inc | HOLD | 0 @ USD 25.52 | USD 0 | The current share valuation price of EWTX based on adjusted close was USD 25.52. The average price that EWTX shares were previous bought at was USD 16.5157. The current market price is 54.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Edgewise Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 44.21 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 44.21. The average price that EXEL shares were previous bought at was USD 41.1499. The current market price is 7.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| EYPT - Eyepoint Pharmaceuticals Inc | HOLD | 0 @ USD 14.79 | USD 0 | The current share valuation price of EYPT based on adjusted close was USD 14.79. The average price that EYPT shares were previous bought at was USD 9.19439. The current market price is 60.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Eyepoint Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| FATE - Fate Therapeutics Inc | HOLD | 0 @ USD 1.09999 | USD 0 | The current share valuation price of FATE based on adjusted close was USD 1.09999. The average price that FATE shares were previous bought at was USD 1.16897. The current market price is -5.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Fate Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 10.99 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 10.99. The average price that FDMT shares were previous bought at was USD 6.85048. The current market price is 60.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of 4D Molecular Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| FOLD - Amicus Therapeutics Inc | HOLD | 0 @ USD 10.02 | USD 0 | The current share valuation price of FOLD based on adjusted close was USD 10.02. The average price that FOLD shares were previous bought at was USD 7.57859. The current market price is 32.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Amicus Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 12.63 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 12.63. The average price that FTRE shares were previous bought at was USD 7.11313. The current market price is 77.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.19 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.19. The average price that GERN shares were previous bought at was USD 1.4743. The current market price is -19.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Geron Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 107.79 | USD 0 | The current share valuation price of GH based on adjusted close was USD 107.79. The average price that GH shares were previous bought at was USD 59.7067. The current market price is 80.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 127.51 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 127.51. The average price that GILD shares were previous bought at was USD 114.096. The current market price is 11.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GLPG - Galapagos NV ADR | HOLD | 0 @ USD 31.13 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.13. The average price that GLPG shares were previous bought at was USD 29.328. The current market price is 6.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Galapagos NV ADR however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GLPG - Galapagos N.V. | HOLD | 0 @ USD 31.13 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.13. The average price that GLPG shares were previous bought at was USD 29.328. The current market price is 6.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Galapagos N.V. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GMAB - Genmab AS | HOLD | 0 @ USD 31.92 | USD 0 | The current share valuation price of GMAB based on adjusted close was USD 31.92. The average price that GMAB shares were previous bought at was USD 24.1267. The current market price is 32.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Genmab AS however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | HOLD | 0 @ USD 34.22 | USD 0 | The current share valuation price of GPCR based on adjusted close was USD 34.22. The average price that GPCR shares were previous bought at was USD 24.2076. The current market price is 41.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Structure Therapeutics Inc. American Depositary Shares however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 110.16 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 110.16. The average price that GRAL shares were previous bought at was USD 56.294. The current market price is 95.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of GRAIL, LLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| GRFS - Grifols SA ADR | HOLD | 0 @ USD 8.78 | USD 0 | The current share valuation price of GRFS based on adjusted close was USD 8.78. The average price that GRFS shares were previous bought at was USD 9.33781. The current market price is -6.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Grifols SA ADR however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 72.66 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 72.66. The average price that HALO shares were previous bought at was USD 60.7917. The current market price is 19.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| HCM - HUTCHMED China Ltd | HOLD | 0 @ USD 14.32 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 14.32. The average price that HCM shares were previous bought at was USD 15.3939. The current market price is -7.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of HUTCHMED China Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| HCM - Hitachi Construction Machinery Co. Ltd | HOLD | 0 @ USD 14.32 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 14.32. The average price that HCM shares were previous bought at was USD 15.3939. The current market price is -7.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Hitachi Construction Machinery Co. Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 35.56 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 35.56. The average price that HRMY shares were previous bought at was USD 32.1335. The current market price is 10.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| HROW - Harrow Health Inc | HOLD | 0 @ USD 41.3 | USD 0 | The current share valuation price of HROW based on adjusted close was USD 41.3. The average price that HROW shares were previous bought at was USD 34.0273. The current market price is 21.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Harrow Health Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.33 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.33. The average price that HUMA shares were previous bought at was USD 2.12959. The current market price is -37.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of Humacyte Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.13 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.13. The average price that IBRX shares were previous bought at was USD 2.70547. The current market price is -21.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 35.88 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 35.88. The average price that IDYA shares were previous bought at was USD 24.3942. The current market price is 47.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 129.81 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 129.81. The average price that ILMN shares were previous bought at was USD 99.9624. The current market price is 29.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 40.13 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 40.13. The average price that IMCR shares were previous bought at was USD 33.3617. The current market price is 20.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Immunocore Holdings Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IMVT - Immunovant Inc | HOLD | 0 @ USD 23.7 | USD 0 | The current share valuation price of IMVT based on adjusted close was USD 23.7. The average price that IMVT shares were previous bought at was USD 18.485. The current market price is 28.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Immunovant Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 105.65 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 105.65. The average price that INCY shares were previous bought at was USD 77.0648. The current market price is 37.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 204.51 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 204.51. The average price that INSM shares were previous bought at was USD 127.296. The current market price is 60.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Insmed Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| INVA - Innoviva Inc | HOLD | 0 @ USD 21.71 | USD 0 | The current share valuation price of INVA based on adjusted close was USD 21.71. The average price that INVA shares were previous bought at was USD 19.1944. The current market price is 13.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Innoviva Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 82.7 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 82.7. The average price that IONS shares were previous bought at was USD 51.0314. The current market price is 62.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Ionis Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.44 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.44. The average price that IOVA shares were previous bought at was USD 2.43792. The current market price is 0.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| IRON - Ironveld Plc | HOLD | 0 @ USD 93.75 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 93.75. The average price that IRON shares were previous bought at was USD 61.4919. The current market price is 52.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Ironveld Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 34.69 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 34.69. The average price that JANX shares were previous bought at was USD 28.0144. The current market price is 23.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| JAZZ - Jazz Pharmaceuticals PLC | HOLD | 0 @ USD 176.92 | USD 0 | The current share valuation price of JAZZ based on adjusted close was USD 176.92. The average price that JAZZ shares were previous bought at was USD 127.33. The current market price is 38.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Jazz Pharmaceuticals PLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| KALV - Kalvista Pharmaceuticals Inc | HOLD | 0 @ USD 14.1 | USD 0 | The current share valuation price of KALV based on adjusted close was USD 14.1. The average price that KALV shares were previous bought at was USD 12.5057. The current market price is 12.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Kalvista Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 42.54 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 42.54. The average price that KNSA shares were previous bought at was USD 30.9748. The current market price is 37.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| KROS - Keros Therapeutics Inc | HOLD | 0 @ USD 17.5 | USD 0 | The current share valuation price of KROS based on adjusted close was USD 17.5. The average price that KROS shares were previous bought at was USD 14.1005. The current market price is 24.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Keros Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| KRYS - Krystal Biotech Inc | HOLD | 0 @ USD 218.7 | USD 0 | The current share valuation price of KRYS based on adjusted close was USD 218.7. The average price that KRYS shares were previous bought at was USD 165.577. The current market price is 32.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Krystal Biotech Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 11.99 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 11.99. The average price that KURA shares were previous bought at was USD 7.61862. The current market price is 57.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| KYMR - Kymera Therapeutics Inc | HOLD | 0 @ USD 67.86 | USD 0 | The current share valuation price of KYMR based on adjusted close was USD 67.86. The average price that KYMR shares were previous bought at was USD 48.3912. The current market price is 40.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Kymera Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| LEGN - Legend Biotech Corp | HOLD | 0 @ USD 27.5 | USD 0 | The current share valuation price of LEGN based on adjusted close was USD 27.5. The average price that LEGN shares were previous bought at was USD 34.1405. The current market price is -19.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of Legend Biotech Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 206.16 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 206.16. The average price that LGND shares were previous bought at was USD 139.821. The current market price is 47.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| LXRX - Lexicon Pharmaceuticals Inc | HOLD | 0 @ USD 1.43 | USD 0 | The current share valuation price of LXRX based on adjusted close was USD 1.43. The average price that LXRX shares were previous bought at was USD 1.09672. The current market price is 30.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Lexicon Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 24.41 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 24.41. The average price that LYEL shares were previous bought at was USD 6.98937. The current market price is 249.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Lyell Immunopharma Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MDGL - Madrigal Pharmaceuticals Inc | HOLD | 0 @ USD 601.03 | USD 0 | The current share valuation price of MDGL based on adjusted close was USD 601.03. The average price that MDGL shares were previous bought at was USD 369.265. The current market price is 62.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Madrigal Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 606.6 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 606.6. The average price that MEDP shares were previous bought at was USD 414.113. The current market price is 46.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MGNX - MacroGenics Inc | HOLD | 0 @ USD 1.48 | USD 0 | The current share valuation price of MGNX based on adjusted close was USD 1.48. The average price that MGNX shares were previous bought at was USD 1.56542. The current market price is -5.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of MacroGenics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MGTX - MeiraGTx Holdings PLC | HOLD | 0 @ USD 8.19999 | USD 0 | The current share valuation price of MGTX based on adjusted close was USD 8.19999. The average price that MGTX shares were previous bought at was USD 7.27084. The current market price is 12.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of MeiraGTx Holdings PLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MIRM - Mirum Pharmaceuticals Inc | HOLD | 0 @ USD 73.13 | USD 0 | The current share valuation price of MIRM based on adjusted close was USD 73.13. The average price that MIRM shares were previous bought at was USD 57.0019. The current market price is 28.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Mirum Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 43.36 | USD 0 | The current share valuation price of MLYS based on adjusted close was USD 43.36. The average price that MLYS shares were previous bought at was USD 21.4544. The current market price is 102.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Mineralys Therapeutics, Inc. Common Stock however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MNKD - MannKind Corp | HOLD | 0 @ USD 5.38 | USD 0 | The current share valuation price of MNKD based on adjusted close was USD 5.38. The average price that MNKD shares were previous bought at was USD 4.75758. The current market price is 13.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of MannKind Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MNMD - Mind Medicine Inc | HOLD | 0 @ USD 12.1 | USD 0 | The current share valuation price of MNMD based on adjusted close was USD 12.1. The average price that MNMD shares were previous bought at was USD 8.89592. The current market price is 36.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Mind Medicine Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 25.01 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 25.01. The average price that MRNA shares were previous bought at was USD 28.8143. The current market price is -13.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MRSN - Mersana Therapeutics Inc | HOLD | 0 @ USD 27.5399 | USD 0 | The current share valuation price of MRSN based on adjusted close was USD 27.5399. The average price that MRSN shares were previous bought at was USD 0.794797. The current market price is 3,365.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Mersana Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 96.09 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 96.09. The average price that MRUS shares were previous bought at was USD 66.9798. The current market price is 43.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Merus BV however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.64 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.64. The average price that MRVI shares were previous bought at was USD 2.79452. The current market price is 30.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| MXCT - MaxCyte Inc | HOLD | 0 @ USD 1.75 | USD 0 | The current share valuation price of MXCT based on adjusted close was USD 1.75. The average price that MXCT shares were previous bought at was USD 2.11843. The current market price is -17.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of MaxCyte Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 151.58 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 151.58. The average price that NBIX shares were previous bought at was USD 131.164. The current market price is 15.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NRIX - Nurix Therapeutics Inc | HOLD | 0 @ USD 17.2 | USD 0 | The current share valuation price of NRIX based on adjusted close was USD 17.2. The average price that NRIX shares were previous bought at was USD 12.3365. The current market price is 39.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Nurix Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 8.52001 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 8.52001. The average price that NTLA shares were previous bought at was USD 12.0577. The current market price is -29.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Intellia Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 109.06 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 109.06. The average price that NUVL shares were previous bought at was USD 84.4469. The current market price is 29.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Nuvalent Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.95 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.95. The average price that NVAX shares were previous bought at was USD 7.30729. The current market price is -4.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.95 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.95. The average price that NVAX shares were previous bought at was USD 7.30729. The current market price is -4.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 12.76 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 12.76. The average price that NVCR shares were previous bought at was USD 16.2317. The current market price is -21.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 1.86 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 1.86. The average price that OABI shares were previous bought at was USD 1.89024. The current market price is -1.6% lower than average price they were purchased at. USD 0 compared to the previous valuation of OmniAb Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| OCUL - Ocular Therapeutix Inc | HOLD | 0 @ USD 12.14 | USD 0 | The current share valuation price of OCUL based on adjusted close was USD 12.14. The average price that OCUL shares were previous bought at was USD 10.1687. The current market price is 19.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Ocular Therapeutix Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| OKUR - OKUR | HOLD | 0 @ USD 2.86 | USD 0 | The current share valuation price of OKUR based on adjusted close was USD 2.86. The average price that OKUR shares were previous bought at was USD 5.91605. The current market price is -51.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of OKUR however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| OLMA - Olema Pharmaceuticals Inc | HOLD | 0 @ USD 28.12 | USD 0 | The current share valuation price of OLMA based on adjusted close was USD 28.12. The average price that OLMA shares were previous bought at was USD 6.85346. The current market price is 310.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Olema Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ORIC - Oric Pharmaceuticals Inc | HOLD | 0 @ USD 11.82 | USD 0 | The current share valuation price of ORIC based on adjusted close was USD 11.82. The average price that ORIC shares were previous bought at was USD 10.5982. The current market price is 11.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Oric Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 2.39 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 2.39. The average price that PACB shares were previous bought at was USD 1.58278. The current market price is 51.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 43.23 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 43.23. The average price that PAHC shares were previous bought at was USD 29.8197. The current market price is 45.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Phibro Animal Health Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PCRX - Pacira BioSciences, Inc. | HOLD | 0 @ USD 23.81 | USD 0 | The current share valuation price of PCRX based on adjusted close was USD 23.81. The average price that PCRX shares were previous bought at was USD 23.7801. The current market price is 0.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Pacira BioSciences, Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PCVX - Vaxcyte Inc | HOLD | 0 @ USD 49.65 | USD 0 | The current share valuation price of PCVX based on adjusted close was USD 49.65. The average price that PCVX shares were previous bought at was USD 44.9144. The current market price is 10.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Vaxcyte Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PGEN - Precigen Inc | HOLD | 0 @ USD 3.74 | USD 0 | The current share valuation price of PGEN based on adjusted close was USD 3.74. The average price that PGEN shares were previous bought at was USD 2.47921. The current market price is 50.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Precigen Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PHAT - Phathom Pharmaceuticals Inc | HOLD | 0 @ USD 15.17 | USD 0 | The current share valuation price of PHAT based on adjusted close was USD 15.17. The average price that PHAT shares were previous bought at was USD 9.57937. The current market price is 58.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Phathom Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PLRX - Pliant Therapeutics Inc | HOLD | 0 @ USD 1.57999 | USD 0 | The current share valuation price of PLRX based on adjusted close was USD 1.57999. The average price that PLRX shares were previous bought at was USD 1.5063. The current market price is 4.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Pliant Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 188.54 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 188.54. The average price that PRAX shares were previous bought at was USD 73.9258. The current market price is 155.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 3.71 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 3.71. The average price that PRME shares were previous bought at was USD 4.47313. The current market price is -17.1% lower than average price they were purchased at. USD 0 compared to the previous valuation of Prime Medicine, Inc. Common Stock however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 10.43 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 10.43. The average price that PRTA shares were previous bought at was USD 9.13781. The current market price is 14.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Prothena Corporation plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 86.25 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 86.25. The average price that PTCT shares were previous bought at was USD 57.1744. The current market price is 50.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| PTGX - Protagonist Therapeutics Inc | HOLD | 0 @ USD 90.07 | USD 0 | The current share valuation price of PTGX based on adjusted close was USD 90.07. The average price that PTGX shares were previous bought at was USD 59.3983. The current market price is 51.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Protagonist Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| QURE - Uniqure NV | HOLD | 0 @ USD 27.63 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 27.63. The average price that QURE shares were previous bought at was USD 23.4213. The current market price is 18.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Uniqure NV however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RARE - Ultragenyx | HOLD | 0 @ USD 33.76 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 33.76. The average price that RARE shares were previous bought at was USD 35.9796. The current market price is -6.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Ultragenyx however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RARE - WISETFWTMRARETFP | HOLD | 0 @ USD 33.76 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 33.76. The average price that RARE shares were previous bought at was USD 35.9796. The current market price is -6.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of WISETFWTMRARETFP however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 3.28999 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 3.28999. The average price that RCKT shares were previous bought at was USD 4.92769. The current market price is -33.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Rocket Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 784.61 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 784.61. The average price that REGN shares were previous bought at was USD 634.432. The current market price is 23.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| REPL - Replimune Group Inc | HOLD | 0 @ USD 10.06 | USD 0 | The current share valuation price of REPL based on adjusted close was USD 10.06. The average price that REPL shares were previous bought at was USD 8.90194. The current market price is 13.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Replimune Group Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 13.26 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 13.26. The average price that RGNX shares were previous bought at was USD 9.45114. The current market price is 40.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.03 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.03. The average price that RLAY shares were previous bought at was USD 4.39537. The current market price is 82.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RNA - Avidity Biosciences Inc | HOLD | 0 @ USD 71.56 | USD 0 | The current share valuation price of RNA based on adjusted close was USD 71.56. The average price that RNA shares were previous bought at was USD 40.4255. The current market price is 77.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Avidity Biosciences Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ROIV - Roivant Sciences Ltd | HOLD | 0 @ USD 20.87 | USD 0 | The current share valuation price of ROIV based on adjusted close was USD 20.87. The average price that ROIV shares were previous bought at was USD 13.6907. The current market price is 52.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Roivant Sciences Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 39.84 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 39.84. The average price that RPRX shares were previous bought at was USD 35.9837. The current market price is 10.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 77.58 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 77.58. The average price that RVMD shares were previous bought at was USD 44.1946. The current market price is 75.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Revolution Medicines Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.41 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.41. The average price that RXRX shares were previous bought at was USD 5.66681. The current market price is -22.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 107.42 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 107.42. The average price that RYTM shares were previous bought at was USD 78.3311. The current market price is 37.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SANA - Sana Biotechnology Inc | HOLD | 0 @ USD 4.02 | USD 0 | The current share valuation price of SANA based on adjusted close was USD 4.02. The average price that SANA shares were previous bought at was USD 3.25775. The current market price is 23.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Sana Biotechnology Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 6.04 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 6.04. The average price that SIGA shares were previous bought at was USD 6.73077. The current market price is -10.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of SIGA Technologies Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SMMT - Summit Therapeutics PLC | HOLD | 0 @ USD 17.82 | USD 0 | The current share valuation price of SMMT based on adjusted close was USD 17.82. The average price that SMMT shares were previous bought at was USD 21.0725. The current market price is -15.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Summit Therapeutics PLC however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SNDX - Syndax Pharmaceuticals Inc | HOLD | 0 @ USD 19.87 | USD 0 | The current share valuation price of SNDX based on adjusted close was USD 19.87. The average price that SNDX shares were previous bought at was USD 12.2987. The current market price is 61.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Syndax Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SNY - Sanofi ADR | HOLD | 0 @ USD 50.03 | USD 0 | The current share valuation price of SNY based on adjusted close was USD 50.03. The average price that SNY shares were previous bought at was USD 50.0556. The current market price is -0.1% lower than average price they were purchased at. USD 0 compared to the previous valuation of Sanofi ADR however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SPRY - Silverback Therapeutics Inc | HOLD | 0 @ USD 9.57 | USD 0 | The current share valuation price of SPRY based on adjusted close was USD 9.57. The average price that SPRY shares were previous bought at was USD 13.21. The current market price is -27.6% lower than average price they were purchased at. USD 0 compared to the previous valuation of Silverback Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 20.95 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 20.95. The average price that SRPT shares were previous bought at was USD 32.505. The current market price is -35.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 43.15 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 43.15. The average price that SRRK shares were previous bought at was USD 35.5021. The current market price is 21.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Scholar Rock Holding Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 31.21 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 31.21. The average price that STOK shares were previous bought at was USD 17.0884. The current market price is 82.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| STRO - Sutro Biopharma | HOLD | 0 @ USD 0.886293 | USD 0 | The current share valuation price of STRO based on adjusted close was USD 0.886293. The average price that STRO shares were previous bought at was USD 0.89707. The current market price is -1.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Sutro Biopharma however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 46.26 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 46.26. The average price that SUPN shares were previous bought at was USD 38.1839. The current market price is 21.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SVRA - Savara Inc | HOLD | 0 @ USD 5.36 | USD 0 | The current share valuation price of SVRA based on adjusted close was USD 5.36. The average price that SVRA shares were previous bought at was USD 3.03658. The current market price is 76.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Savara Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| SYRE - Spyre Therapeutics Inc. | HOLD | 0 @ USD 29.75 | USD 0 | The current share valuation price of SYRE based on adjusted close was USD 29.75. The average price that SYRE shares were previous bought at was USD 18.3688. The current market price is 62.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Spyre Therapeutics Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TARS - Tarsus Pharmaceuticals Inc | HOLD | 0 @ USD 80.5 | USD 0 | The current share valuation price of TARS based on adjusted close was USD 80.5. The average price that TARS shares were previous bought at was USD 51.6617. The current market price is 55.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Tarsus Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TBPH - Theravance Biopharma Inc | HOLD | 0 @ USD 19.96 | USD 0 | The current share valuation price of TBPH based on adjusted close was USD 19.96. The average price that TBPH shares were previous bought at was USD 12.4353. The current market price is 60.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Theravance Biopharma Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TERN - Tern Plc | HOLD | 0 @ USD 28.75 | USD 0 | The current share valuation price of TERN based on adjusted close was USD 28.75. The average price that TERN shares were previous bought at was USD 7.24803. The current market price is 296.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Tern Plc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TNGX - Tango Therapeutics Inc | HOLD | 0 @ USD 10.76 | USD 0 | The current share valuation price of TNGX based on adjusted close was USD 10.76. The average price that TNGX shares were previous bought at was USD 6.55433. The current market price is 64.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Tango Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TRDA - Entrada Therapeutics Inc | HOLD | 0 @ USD 10.08 | USD 0 | The current share valuation price of TRDA based on adjusted close was USD 10.08. The average price that TRDA shares were previous bought at was USD 7.81022. The current market price is 29.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Entrada Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TSHA - Taysha Gene Therapies Inc | HOLD | 0 @ USD 4.86 | USD 0 | The current share valuation price of TSHA based on adjusted close was USD 4.86. The average price that TSHA shares were previous bought at was USD 2.99711. The current market price is 62.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Taysha Gene Therapies Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TVTX - Travere Therapeutics Inc | HOLD | 0 @ USD 36.26 | USD 0 | The current share valuation price of TVTX based on adjusted close was USD 36.26. The average price that TVTX shares were previous bought at was USD 21.2616. The current market price is 70.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Travere Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 31.7 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 31.7. The average price that TWST shares were previous bought at was USD 35.5826. The current market price is -10.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 18.75 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 18.75. The average price that TXG shares were previous bought at was USD 12.6488. The current market price is 48.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 18.75 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 18.75. The average price that TXG shares were previous bought at was USD 12.6488. The current market price is 48.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 29.42 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 29.42. The average price that URGN shares were previous bought at was USD 15.6796. The current market price is 87.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of UroGen Pharma Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 488.43 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 488.43. The average price that UTHR shares were previous bought at was USD 355.528. The current market price is 37.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VCEL - Vericel Corp Ord | HOLD | 0 @ USD 40.37 | USD 0 | The current share valuation price of VCEL based on adjusted close was USD 40.37. The average price that VCEL shares were previous bought at was USD 40.7134. The current market price is -0.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Vericel Corp Ord however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 47.71 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 47.71. The average price that VCYT shares were previous bought at was USD 32.3836. The current market price is 47.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VERA - Vera Therapeutics Inc | HOLD | 0 @ USD 33.33 | USD 0 | The current share valuation price of VERA based on adjusted close was USD 33.33. The average price that VERA shares were previous bought at was USD 27.0717. The current market price is 23.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Vera Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 6.39 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.39. The average price that VIR shares were previous bought at was USD 5.8425. The current market price is 9.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 6.39 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.39. The average price that VIR shares were previous bought at was USD 5.8425. The current market price is 9.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 5.30001 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 5.30001. The average price that VNDA shares were previous bought at was USD 4.87022. The current market price is 8.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 432.17 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 432.17. The average price that VRTX shares were previous bought at was USD 416.603. The current market price is 3.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VTRS - Viatris Inc | HOLD | 0 @ USD 10.64 | USD 0 | The current share valuation price of VTRS based on adjusted close was USD 10.64. The average price that VTRS shares were previous bought at was USD 9.68554. The current market price is 9.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Viatris Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 4.02999 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 4.02999. The average price that VYGR shares were previous bought at was USD 3.8785. The current market price is 3.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Voyager Therapeutics Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| WVE - Wave Life Sciences Ltd | HOLD | 0 @ USD 7.67 | USD 0 | The current share valuation price of WVE based on adjusted close was USD 7.67. The average price that WVE shares were previous bought at was USD 8.33467. The current market price is -8.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Wave Life Sciences Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| XENE - Xenon Pharmaceuticals Inc | HOLD | 0 @ USD 44.49 | USD 0 | The current share valuation price of XENE based on adjusted close was USD 44.49. The average price that XENE shares were previous bought at was USD 36.1706. The current market price is 23.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Xenon Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| XERS - Xeris Pharmaceuticals Inc | HOLD | 0 @ USD 7.18 | USD 0 | The current share valuation price of XERS based on adjusted close was USD 7.18. The average price that XERS shares were previous bought at was USD 6.14203. The current market price is 16.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Xeris Pharmaceuticals Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| XNCR - Xencor Inc | HOLD | 0 @ USD 17.38 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 17.38. The average price that XNCR shares were previous bought at was USD 11.6001. The current market price is 49.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Xencor Inc however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ZLAB - Zai Lab Ltd | HOLD | 0 @ USD 19.97 | USD 0 | The current share valuation price of ZLAB based on adjusted close was USD 19.97. The average price that ZLAB shares were previous bought at was USD 33.0089. The current market price is -39.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of Zai Lab Ltd however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 27.33 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 27.33. The average price that ZYME shares were previous bought at was USD 15.3887. The current market price is 77.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-11-27 this would crystalise an overall loss. |